The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC).
 
Andre Poisl Fay
No Relationships to Disclose
 
Eliezer Mendel Van Allen
No Relationships to Disclose
 
Bradley Murray
No Relationships to Disclose
 
Laurence Albiges
Consulting or Advisory Role - Amgen; Novartis; Pfizer; Sanofi
Speakers' Bureau - Novartis; Pfizer
Research Funding - novartis; pfizer
Travel, Accommodations, Expenses - Amgen; Novartis
 
Sabina Signoretti
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Verastem
 
Thai Huu Ho
No Relationships to Disclose
 
A. Ari Hakimi
No Relationships to Disclose
 
Suzanne S Mickey
No Relationships to Disclose
 
Melissa L. Stanton
No Relationships to Disclose
 
Joaquim Bellmunt
Consulting or Advisory Role - Genentech; Merck; Pierre Fabre
Research Funding - Millennium/Prometrika; Takeda
 
David F. McDermott
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche; Merck; Pfizer
Research Funding - Prometheus
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Amgen; C-Cam; Genentech; GlaxoSmithKline; Lilly; Merck; Neostem; Novartis; Novartis; Pfizer; X4 Pharma
 
Levi A. Garraway
No Relationships to Disclose
 
David J. Kwiatkowski
Consulting or Advisory Role - Novartis
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer